LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in the Bermuda with limited liability)

(Stock Code: 02186)

VOLUNTARY ANNOUNCEMENT

ACCEPTANCE OF THE NDA FOR LURBINECTEDIN BY NMPA IN CHINA

The board of directors (the "**Board**") of Luye Pharma Group Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") announces that the New Drug Application ("**NDA**") of Lurbinectedin for injection ("**Lurbinectedin**" or "**LY01017**"), an imported drug the Group licensed from Pharma Mar, S.A. ("**PharmaMar**"), has been accepted by the Centre for Drug Evaluation ("**CDE**") of the National Medical Products Administration ("**NMPA**") in the People's Republic of China ("**China**") for the treatment of adult patients with metastatic small cell lung cancer ("**SCLC**") with disease progression on or after receiving platinum-based chemotherapy. Previously, the drug has been granted priority review by the NMPA.

Lurbinectedin is a selective inhibitor of oncogenic transcription. Its unique dual-action mechanism allows it to regulate the microenvironment for tumors, while inhibiting oncogenic transcription and leading to the apoptosis of cancer cells. In 2020, Lurbinectedin received the Accelerated Approval from the **United States (U.S.)** Food and Drug Administration ("**FDA**") for the above indication.

The NDA is based on data from a single-arm, dose-escalation, and dose-expansion clinical study conducted in China. The study was designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of Lurbinectedin in Chinese patients with advanced solid tumors including relapsed SCLC. The results of the study show promising efficacy and a manageable safety profile of the drug as a second-line therapy at a dose of 3.2mg/m^2 in Chinese SCLC patients. An Independent Review Committee confirmed the Overall Response Rate ("**ORR**") was 45.5% in subjects with relapsed SCLC.

Lung cancer was reported to be China's No. 1 cancer in 2020 in terms of morbidity and mortality, with approximately 815,000 new reported cases and 714,000 deaths that year. Specifically, SCLC accounted for 13%–17% of all lung cancer cases. Most SCLC patients were already in the advanced stage upon diagnosis, resulting in poor prognosis. Their five-year survival rate was only 7% or as low as 3% for those in the extensive stage. Although SCLC is very sensitive to initial treatments, most patients would experience a relapse or develop drug resistance after initial treatments. According to statistics, approximately 75% of the patients with locally advanced SCLC and more than 90% of those with metastatic SCLC would relapse within two years after receiving treatments. The high relapse rate of SCLC poses a significant challenge to its treatment, and innovative therapies are urgently needed in clinical practice.

Lurbinectedin has been the only new chemical entity approved by the FDA for the treatment of relapsed SCLC during the past 26 years since 1997 as far as the Company is aware. The approval of Lurbinectedin in the U.S. was based on data from an open-label, multicenter, and single-arm Phase II clinical study of the drug in 105 adult patients with SCLC (including platinum-sensitive and platinum-resistant ones) whose disease progressed after receiving platinum-based chemotherapy. In this study, patients treated with Lurbinectedin demonstrated an ORR of 35% and a median Duration of Response (DoR) of 5.3 months.

The aforesaid clinical study conducted in China was, as far as the Company is aware, the first study evaluating the efficacy and safety of Lurbinectedin in Chinese patients. The results show that the efficacy of Lurbinectedin in Chinese patients with relapsed SCLC who had experienced progression after receiving the first-line platinum-based chemotherapy was comparable to its efficacy in the Phase II clinical study conducted overseas, and the response rate was even higher in Chinese patients. The preliminary results of the Chinese study were presented at the 2022 annual meeting of the American Society of Clinical Oncology as well as the 25th National Clinical Oncology Conference and the 2022 annual meeting of the Chinese Society of Clinical Oncology, attracting extensive attention from both Chinese and overseas experts.

In addition to the Chinese mainland, Lurbinectedin is also being reviewed for its NDA in the Hong Kong SAR of China. Moreover, the drug is available to Chinese patients for urgent clinical use at designated medical institutions in the Hainan Boao Lecheng International Medical Tourism Pilot Zone and through the Named Patient Program in Hong Kong.

The Company believes that Lurbinectedin meets the current urgent clinical needs and has good market potential. At the same time, this product will further enrich the Group's product pipelines in oncology, and cooperate with the Group's existing resources and advantages in oncology to accelerate the Company's coverage and development in this field.

ABOUT LURBINECTEDIN

Lurbinectedin is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinacidia turbinata in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, Lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor.

Lurbinectedin has also been approved in nine other countries, in addition to its accelerated approval by the FDA for the treatment of metastatic SCLC. The drug is recommended by Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (published in 2021) and the NCCN Guidelines for Small Cell Lung Cancer (2022). The Group owns the rights to develop and commercialize Lurbinectedin in China.

ABOUT PHARMAMAR

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has by itself developed and commercialized Yondelis® in Europe and in conjunction with business parties, Zepzelca® (Lurbinectedin) in the U.S. and China as well as Aplidin® (Plitidepsin) in Australia. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: namely, Lurbinectedin and Ecubectedin. Headquartered in Madrid, Spain, PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and the U.S.. PharmaMar also wholly owns Sylentis, a company dedicated to researches on therapeutic applications of gene silencing (RNAi).

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 6 June 2023

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. SUN Xin; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.